Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3874288 | 0.89 | PTGS2 (0.48) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL4321256 | 0.86 | PTGS2 (0.40) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL4308029 | 0.85 | PTGS2 (0.39) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL4325069 | 0.84 | PTGS2 (0.39) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL4312746 | 0.76 | PTGS2 (0.49) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL4312100 | 0.75 | CYP2C9 (0.34) | — | |
| SCHEMBL3869145 | 0.74 | PTGS2 (0.53) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL3870142 | 0.73 | PTGS2 (0.52) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL4311949 | 0.72 | PTGS2 (0.46) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL3869939 | 0.72 | PTGS2 (0.51) | PTGS2PTGS1ABCB11PPARGNR1I3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140058129-A1 | Phenylacetic Acid Derivatives | NOVARTIS AG (CH) | 2014-02-27 | — | — | US | disclosed |
| US-8586782-B2 | Phenylacetic acid derivatives | NOVARTIS AG (CH) | 2013-11-19 | — | — | US | disclosed |
| US-8362294-B2 | Phenylacetic acid derivatives | NOVARTIS AG (CH) | 2013-01-29 | — | — | US | disclosed |
| US-20130012585-A1 | Phenylacetic Acid Derivatives | MONOVICH LAUREN G (US) | 2013-01-10 | — | — | US | disclosed |
| EP-2046723-B1 | PHENYLACETIC ACID DERIVATIVES AS COX-2 INHIBITORS | NOVARTIS AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| US-20090209648-A1 | Phenylacetic Acid Derivatives | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140058129-A1 | Phenylacetic Acid Derivatives | PTGES2, PTGS2, GOT2 | PTGS2 2/4885PTGS1 8/4885ABCB11 211/4885 |
| US-20130012585-A1 | Phenylacetic Acid Derivatives | PTGES2, PTGS2, GOT2 | PTGS2 2/4885PTGS1 8/4885ABCB11 211/4885 |
| US-20090209648-A1 | Phenylacetic Acid Derivatives | PTGES2, PTGS2, PTGER2 | PTGS2 2/4885PTGS1 8/4885ABCB11 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.